Member Info for elrico

Wolf-of-BS-street....I actually blushed when I read your post. I don't embarrass easily, but I felt as though I have been caught in a lie, not you. That is the measure of your stupidity. On the upside....no damage done; It's not as though you had a credibility.

OPTI starting to transition their website. Looking really cool. The investor part will change mid of next week to look the same. This is part of the transition to communicate to commercial partners etc. hence a corporate site is now needed. Next stage online platform with the Appointment of Steven Riley. http://optibiotix.com/

Revolution - that is SOH spin on the accounting period. Personally I don't have an issue with the perceived delay, because CH states the deadline as 31st May. However, I do understand some PI's may get twitchy when they don't see the same accounting dates. We do like a predictive pattern.

Trek - we may be slightly cross purposes on this one. From memory, SBTX IPO cost c�233k, plus had the effect of increased losses for the period, this included the cost associated with the transfer of OPTI SKIN to SBTX, which to the untrained eye, can appear as a cash loss. Again, from memory, interim cash was �1.9+m. OPTI still retain 42% of SBTX, which must be worth c�7m+ at today's price at a cost of �250k. So, if OPTI did need funding (which has been denied countless times by SOH) then they have the option to sell some or all of SBTX. I don't envisiage this, but if they did, I'm pretty sure it would be well north of today's price. SOH has made it clear his next preferred IPO is SweetBiotix (open to trade sale - but I really do not see this happening) which has the potential to outshine SBTX in terms of IPO value, and PI appetite for a hot topic. I would imagine the funding for the IPO would be similar to that of SBTX AND OF COURSE, the potential for a much greater asset on OPTI's books. Of course, a significant transfer of IP would result in increased losses, just as SBTX. My comment about II eagerness for OPTI blocks is not my opinion, it is that of SOH. He has been pestered by II wanting large blocks, but they want them in one hit and this requires a placing, which SOH has refused. Most PI's don't see the MM games and think other PI's are just conspiracy theorists when we point out odd price movements. I have given two clear trades (2x111,111) as example of MM walking down the SP to fill a large buy. Of course, both appeared as sells, but I know for a fact they were buys because I was privy to them several hours before they showed themselves. Those example were of a wealthy PI, so what power does a II have over the smaller PI! SOH and FinnCap do try to match large sell with a buy, this is not always possible. IMHO FinnCap do not earn their corn in this regard.

2015 accounts were released on May 29th, 2016 on April 14th. This year the accounts are more complex as we listed one of our divisions (SBTX) on April 5th 2017 which is part way through our account year Nov 16-Nov 17

Sorry TM - you demonstrate a big knowledge gap in the way an IPO works. IF OPTI were to spin-out another part of the company, it generates funds, not eats them. Jezz, were you not about with OPTI spun-out SBTX? Cash call will not happen, or SOH looks a complete fool, given the amount of times he's said they don't need funding, at that is exactly what II want, they have been begging for a placing so they can get large blocks. The results will not show any significant cash generation because most of the deals were signed after the interims window. Most of us have not expectation to the contrary.

Nanoco article https://tinyurl.com/yalsoaw6

Some of you will already be familiar, but in case we have new PI's, you may want to visit https://twitter.com/LEMMINGINVESTOR there you will find plenty of research material.

�Demand for probiotics is increasing significantly� 06-Apr-2018 By Aslam Shaikh, senior research analyst, MarketsandMarkets While dairy has traditionally been the most common format for probiotic products, the non-dairy beverages segment is expected to growth at a CAGR of 9.6% from 2017 � 2022. With a rise of more than 30% in sales of refrigerated probiotics drinks and juices since 2016 � including yogurt, HPP juices, almond milk, water, herbal tea and coffee � this guest article puts the spotlight on the growing sector. https://www.beveragedaily.com/News/Markets/SSNL-Demand-for-probiotics-is-increasing-significantly

https://twitter.com/LEMMINGINVESTOR/status/982617336309080066?s=19 Greatly expands on The Times article. There's much more to SweetBiotix than we perhaps were aware of.

SP - Most of your queries are bound by NDA's. Sounds a cop-out, I know. Nowt I can do about that perception. 2015. March. We signed a third agreement with Nizo foods, did anything come of that. A: Much has been misunderstood about the NIZO agreements. Most of the work NIZO undertook, was to filter specific strain for dairy related products, including yogurts. Essentially, help broaden the range of applications for SlimBiome. OPTI signed a JV with them to develop, manufacture and distribute a weight management yoghurt where they provided the manufacturing expertise. 2015. June. We signed an option agreement with a unknown consumer goods company, do you know who that was. A: According to TW, (presumably via AR) this was announced as P&G. SOH have never confirmed this. However, when pressed about this announcement, he confirmed to me the company is on track.....whatever that means. 2015 Nov. JV with an Italian company, CSL, since then nothing. A:CSL, like SACCO, Nutrilliea and now Fine Foods, have specific licenses to manufacture raw ingredients for clients. I would imagine we will see the fruits of all of these partnerships in one form or another in due course, perhaps as soon as the end of April, when the e-commerce site is expected to be launched. 2016 Jan, JV, with KSF. A: AS ABOVE - ONGOING 2016. JV. Royal DSM A: See Nizo role. Similar 2016. JV. TATA. A: LPGOS/TATA - we were informed pilot production (legal term for ironing production teething ahead of full production) was scheduled to commence in Nov 2017 and full production in Dec 2017. As far as I'm aware there has been no change. SlimBiome is a little more complicated. Christina used her expertise to change things up a little, resulting in significant improvements, not just taste, texture and ease of use, but more importantly, heat resistant, which opened up a whole new market. She also put in check and balances and traceability. All this resulted in SlimBiome launch. It you were TATA, would you want to go with an inferior product. IMHO OPTI is way ahead of commercialism, given where it was just over 3.5 years ago. It only embarked on commercial venture May 2017. It would be easy for them to make statements as to when they expected partner products on the shelves. Indeed, I put it to SOH, If Galenicum and HLH were happy to tell me when they planned their product launches, surely it follows this info is not cluded in NDA's, so as a company, you must have some idea when each partner plans to launch, because they have specific clauses in all contracts. SOH came back with the notion a partner may delay due to problems outside OPTI's control and would be bound to make an announcement and thus adversely effect the SP. So, like the revenue visibility, it is frustrating not knowing the inflection point is. It all boils down to trusting the BOD, or not. That and market sentiment. IMHO people focus on the SP and take their eye on the significant det

Belgrano - I'm sure OPTI won't go down with as many hands as The Belgrano. You, as everyone invested on AIM are dam right to maintain a healthy dose of skepticism. The best frauds fronted by very charming, charismatic and affable people, perfectly capable of looking you in the eye and lying to you. I know I have in the past looked a CEO in the eye and he has lied to me. I have learned from that experience, but the signs are ALWAYS there, you just need to keep an open mind and look for the obvious signs, because they usually are very obvious. AIM FRAUD The re-quote you post is on the face of it, valid. However, you still need to look for those signs I elude to. Fraud is usually about money, and typically, it is about issuing new shares with the promise of transitioning a company from R&D to commercial....bang, placing, bump and dump, bucket shop, chop shop and PI's diluted out of their positions. Products never materialise and of course, the big pump....company revenue projections (usually over stated) and typically ahead of a 2nd or 3rd placing. Commercial progress only commenced last may. Since then 9 commercial deals have been announced, almost 1 per month and getting bigger all the time. Why do they take so long ask the cynics? Companies work at their own pace, they need to perform DD on the IP, products, their markets and then negotiate the territories, products, and often there is a conflict, in that 2+ companies may want the same products and or territories. I nice problem for OPTI to have, but it slows the signatures down a little more. SOH has told us several times; c9 months is typical before sign-off and global's can to 12+ months. There are at least 2 US corp's at very late stage, whom have sent VP's (a serious sign of intent) tomeet the BOD in the states a couple of weeks ago. These have been 12+ months in the making. I think many of us are guilty of not appreciating how long it takes to go through the whole process. This frustration is compounded by the lack of revenue visibility. But think about it. Humanbiome is a new science and OPTI are years ahead of the field in terms of science, products and IP/Trademarks. You must product the IP/Trademarks BEFORE anything else, or you have no business. Once you have, then you have new products with new science - there is no historical sale data to fall back on because in some cases, we are breaking new ground here. OK, there is with HLH and Galenicum, because they appear to be adding LP-LDL to existing brands, which have historical sale volume and if the OptiBiotic platform is utilised to enhance existing probiotics, then this has the potential for greater visibility simply because we already have existing historical sales data to fall back, in which you can make "reasonable" assumptions. Imagine at time when SOH comes out with guidance of c�4-6m revenues - Would anyone doubt him? Not a chance. Incidentally, those are my ballpark for FY 2019, NOT SOH's.

Apols if I came across as a misery. I'm still about. An OPTI research group has been set up on twitter. If it takes off it removes the hassle of trolls. https://twitter.com/LEMMINGINVESTOR I can add if you tweet.

Apols if I came across as a misery. I'm still about. An OPTI research group has been set up on twitter. If it takes off it removes the hassle of trolls. https://twitter.com/LEMMINGINVESTOR I can add if you tweet.

Boyzee - I'm not sure what you expect me to do. I am deliberately limiting my time on the forums. Those that know me, know why. When I do have something I feel is worth sharing, I do so privately, like today. Today's overview by SOH and shared by Primal (I chose not). It contained nothing new, yet soothed some PI's. However, this did nothing to reverse the red, not until TW's lemmings followed TW and bought. I found this particularly peculiar, given the missed �1+ target, time after time. However, we have been here before have we not. I remain exceptionally confident in OPTI and her BOD. You may ask why I chose not to share the info Primal did? As I said to SOH, I felt what is needed is a reach RNS, not me posting, not a proactive or directors talk interview because these have limited reach, where an reach RNS holds more weight, is more credible and has a wider reach. It is clear there is far more going on behind the scenes and several interested parties appear to be jostling for the same territories, same products, etc. This may well slow the process down, but it also ensure the best financial outcome for the company. Think of it like Real Madrid and Manchester United bidding for the same player....the selling club can only demand more for the same player. I don't really concern myself with the daily movement of the SP, WHY wpould I when my strategy is one of investment for my retirement, not short term. Good luck.

Both Christina and Per have performance related options. The promo/marketing will kick-off when the group have their products available to market, which I believe is very soon. https://twitter.com/LEMMINGINVESTOR/status/975459948636368898

100k is less than �10k - many retail PI's have that to trade. PI's need to workout if they are investors or traders. Of course you can do both. In any event, SBTX is still at the pre commercial phase, thus still very much a risky punt. Once the human data proves positive you will most likely see hot money entering in larger tranches.

Talk of even .5% of the global market is fanciful at this stage, or even 5 years. There are 1000s of companies in the same space as OPTI. Not to be confused with same science/products. OPTI are years ahead of any company, PLC or private, but there is competition, established and developing. The task OPTI partners have, is persuading their clients they have THE SCIENCE BACKED, PEER reviewed solutions. This takes time, but at no cost to OPTI.

#SlimBiome #OptiBiotix #slimmingworld Weight management technology to reduce weight gain risk of high-sugar cereal products Cutting-edge weight loss technology developed in the UK is going to be used to combat the high sugar and calorie content of cereal products in the US. The SlimBiome weight loss technology, developed by OptiBiotix Health, is a patented functional ingredient which helps people to consistently manage weight loss by reducing food intake, without the usual food cravings. https://twitter.com/LEMMINGINVESTOR/status/974577577124868096

Company CEO Cath O'Neill is to present at the 5th European Microbiome R&D and Business Collaboration Forum which will be held on March 21-22, 2018 in Rotterdam, the Netherlands. @lifesciences_GE #SBTX https://twitter.com/SkinBioT/status/974595221358108674